Please login to the form below

Not currently logged in
Email:
Password:

Zalviso

This page shows the latest Zalviso news and features for those working in and with pharma, biotech and healthcare.

Grunenthal and AcelRx’s Zalviso approved in EU

Grunenthal and AcelRx’s Zalviso approved in EU

Zalviso is a non-invasive, handheld system that allows hospital patients to self-dose with sublingual sufenatil microtablets. ... delivery. AcelRx developed Zalviso and entered into a commercial collaboration with Grunenthal at the end of 2013.

Latest news

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Grünenthal's relentless pursuit of relief Grünenthal's relentless pursuit of relief

    It is our passion to help these patients.”. It is also investing in New Technical Entities (NTEs) which include new formulations and devices, acquiring Zalviso, a combination of a medical device

  • Pharma deals in September 2015 Pharma deals in September 2015

    PDL BioPharma is buying out the majority of the expected royalty stream from EU sales of AcelRX's phase III product, Zalviso for $65m. ... Royalty monetisation. 110. AcelRx Pharmaceuticals. PDL BioPharma. Zalviso sub-lingual formulation of sufentanil.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics